Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Public ClinicalTrials.gov record NCT01968460. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Study identification
- NCT ID
- NCT01968460
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Enrollment
- 149 participants
Conditions and interventions
Conditions
Interventions
- P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), Drug
- P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg), Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 35 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Apr 30, 2015
- Completion
- May 31, 2015
- Last update posted
- Apr 6, 2023
2013 – 2015
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| P2B001 Site Birmingham | Birmingham | Alabama | — | — |
| P2B001 Site Los Angeles | Los Angeles | California | — | — |
| P2B001 Site Aurora | Aurora | Colorado | — | — |
| P2B001 Manchester | Manchester | Connecticut | — | — |
| P2B001 Site New Haven | New Haven | Connecticut | — | — |
| P2B001 Site Boca Raton | Boca Raton | Florida | — | — |
| P2B001 Site Port Charlotte | Port Charlotte | Florida | — | — |
| P2B001 Site Tampa | Tampa | Florida | — | — |
| P2B001 Site Augusta | Augusta | Georgia | — | — |
| P2B001 site Chicago | Chicago | Illinois | 60612 | — |
| P2B001 Site Kansas City | Kansas City | Kansas | — | — |
| P2B001 Site Boston | Boston | Massachusetts | — | — |
| P2B001 Site west Bloomfield | West Bloomfield | Michigan | — | — |
| P2B001 Site Golden Valley | Golden Valley | Minnesota | — | — |
| P2B001 Site Camden | Camden | New Jersey | — | — |
| P2B001 Site New Brunswick | New Brunswick | New Jersey | — | — |
| P2B001 site Commack | Commack | New York | — | — |
| P2B001 Site New York | New York | New York | — | — |
| P2B001 Site Durham | Durham | North Carolina | — | — |
| P2B001 Site Cincinnati | Cincinnati | Ohio | — | — |
| P2B001 Site Toledo | Toledo | Ohio | — | — |
| P2B001 Site Tulsa | Tulsa | Oklahoma | — | — |
| P2B001 Site Houston | Houston | Texas | — | — |
| P2B001 Site Roanoke | Roanoke | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01968460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2023 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01968460 live on ClinicalTrials.gov.